Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells

The imidazolium compound Ym155 was first reported to be a survivin inhibitor. Ym155 potently induces cell death of many types of cancer cells in preclinical studies. However, in phase II clinical trials Ym155 failed to demonstrate a significant benefit. Studies have suggested that the cytotoxic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondal, Arindam, Jia, Dongxuan, Bhatt, Vrushank, Akel, Moumen, Roberge, Jacques, Guo, Jessie Yanxiang, Langenfeld, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338953/
https://www.ncbi.nlm.nih.gov/pubmed/35908087
http://dx.doi.org/10.1038/s41598-022-17446-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338953/
https://www.ncbi.nlm.nih.gov/pubmed/35908087
http://dx.doi.org/10.1038/s41598-022-17446-y

Ejemplares similares